Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.06 USD
+0.22 (7.75%)
Updated May 15, 2024 04:00 PM ET
After-Market: $3.04 -0.02 (-0.65%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GALT 3.06 +0.22(7.75%)
Will GALT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GALT
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
GALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Other News for GALT
GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics GAAP EPS of -$0.19
Galectin Therapeutics reports Q1 EPS (19c) vs (19c) last year
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference